Skip to main content
. 2023 Dec 22;8(24):e173688. doi: 10.1172/jci.insight.173688

Figure 8. Antitumor effect of ROS1-TKIs in the HCC78 xenograft MIG6 depletion model.

Figure 8

(A and B) HCC78 control and MIG6-knockout cells were subcutaneously transplanted into BALB/c nude mice. The mice were treated with vehicle, crizotinib (50 mg/kg) orally, panitumumab (0.5 mg, twice a week) intraperitoneally, or crizotinib plus panitumumab for 4 weeks (n = 5–6). Data are presented as the mean ± SEM; ***P < 0.001 (1-way ANOVA following Dunnett’s test). Images of xenograft tumors on day 28 after the initial treatment are shown in B. The black bar indicates 1 cm.